Terms of the deal have not been disclosed.
NOxBOX manufactures inhaled gas delivery and monitoring instruments for the medical market.
Praxair executive vice president Scott Telesz said: "We are very pleased to have acquired this comprehensive means of delivering and monitoring nitric oxide for patients in need of inhaled nitric oxide therapy.
"The acquisition of this product line is part of our long-term strategy to further broaden our offerings to hospitals and deliver the latest in respiratory healthcare technology to our customers around the world."
The purchase includes the full NOxBOX range of critical care delivery and monitoring devices for inhaled nitric oxide therapy.
The product portfolio includes NOxBOXi delivery system, which enables intelligent delivery of nitric oxide with real-time monitoring of nitric oxide, nitrogen dioxide and oxygen via a touch screen with step-by-step guided interface.
Bedfont managing director Trevor Smith said: "Our NOxBOX range of products will much better be supported by Praxair, a global industrial and medical gas company."
NOxBOX will remain headquartered in the UK and staff members earlier involved will be transferred with the business.
Image: Praxair has acquired UK-based NOxBOX from Bedfont Scientific. Photo: courtesy of Bedfont Scientific Ltd.
